MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

Knight Therapeutics Inc. ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2024.

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Please note that Merck markets Lynparza in partnership with AstraZeneca AZN. Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by ...

Antônio Vinicius Gritzbach had recently agreed to hand over information about the Primeiro Comando da Capital group. Former Brazil and Real Madrid defender Marcelo leaves Brazilian Serie A club ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Venezuela criticises Brazil's decision to veto its admission to the Brics group of emerging economies. Three Americans were arrested, with Venezuela accusing them of working with US spy agencies ...

Lenvima is taking on Bayer's Nexavar in liver cancer in Japan – a drug that has been on the market for around a decade. According to Hendler the uptake in Japan has been remarkable, and more ...